spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  stem cell transplant 

 HSMN NewsFeed - 14 Jun 2024
TALVEY(R) (talquetamab-tgvs) Demonstrates Highly Durable, Longer-Term Responses in Patients with Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Sep 2023
Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration (FDA) regarding the Planned Resubmission of the BLA for LYMPHIR(TM)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Jan 2023
Monica Shaw appointed CEO of Oncopeptides - Jakob Lindberg assumes position as Chief Scientific Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 8 Jul 2022
Sobi to license loncastuximab tesirine from ADC Therapeutics
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 29 Jun 2022
Artax Biopharma Appoints D. Scott Batty, Jr., M.D. as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Dec 2021
FDA Approves First Drug to Prevent Graft Versus Host Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 25 Nov 2021
Priothera Appoints Elisabeth Kueenburg M.D., as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 12 Jul 2021
Janssen Announces U.S. FDA Approval of DARZALEX FASPRO(R) (daratumumab and hyaluronidase-fihj) in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 Feb 2021
The Lancet Publishes Libtayo(R) (cemiplimab) Data Showing Extended Overall Survival in Patients with First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Dec 2020
Soligenix Announces Topline Results from its Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Oct 2020
Priothera closes €30 million Series A financing to develop highly promising therapies for acute myeloid leukemia (AML)
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 18 Sep 2020
BrainCool Announces Statistically Significant Late-Breaking Clinical Data at ESMO Virtual Congress 2020
Devices Oncology
 HSMN NewsFeed - 11 Sep 2020
Targazyme Appoints Jim Caggiano as CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Jun 2020
FDA Clears IND for iNKT Cells to Treat COVID-19 Patients
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Jan 2020
Altavant Sciences Acquires Onspira Therapeutics, Adding a Potentially Life-Saving Treatment for Post-Lung Transplant Patients to the Altavant Pipeline
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 6 Jan 2020
CARsgen Appoints Yong Fan as Senior Vice President of Global Regulatory Affairs
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 12 Aug 2019
CASI Pharmaceuticals Announces Launch of EVOMELA(R) (melphalan for injection) in China
Biopharmaceuticals Oncology Product Launch
 HSMN NewsFeed - 1 Aug 2019
Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo(R) (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Jun 2019
Daiichi Sankyo Provides Update on FDA Review of Quizartinib for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 Jun 2019
Sobi Acquires Emapalumab and Related Assets
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 4 Apr 2019
Daiichi Sankyo Provides Update on Ongoing FDA Review for Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 26 Mar 2019
Breath Therapeutics Announces Initiation of Global Phase 3 Trials for the Treatment of Bronchiolitis Obliterans Syndrome
Biopharmaceuticals
 HSMN NewsFeed - 12 Feb 2019
U.S. FDA Approves DARZALEX(R) (daratumumab) Split-Dosing Regimen
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Jan 2019
European Commission Approves BLINCYTO(R) (blinatumomab) In Patients With Philadelphia Chromosome Negative Minimal Residual Disease-Positive B-cell Precursor Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 20 Nov 2018
FDA Approves Gamifant(R) (emapalumab), the First and Only Treatment for Primary Haemophagocytic Lymphohistiocytosis (HLH)
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Nov 2018
EMA Validates and Grants Accelerated Assessment of Marketing Authorization Application for Daiichi Sankyo's FLT3 Inhibitor Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 29 Aug 2018
European Commission Approves BLINCYTO(R) (blinatumomab) For Use In Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 27 Aug 2018
Vyxeos(R) Receives Marketing Authorisation in the European Union for Treatment of Certain Types of High-Risk Acute Myeloid Leukaemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 8 Aug 2018
Janssen Submits U.S. & EU Regulatory Applications Seeking Approval of DARZALEX(R) (daratumumab) Split Dosing Regimen
Biopharmaceuticals Oncology FDA Regulatory
 HSMN NewsFeed - 1 Aug 2018
FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo's FLT3 Inhibitor Quizartinib for Relapsed/Refractory FLT3-ITD AML
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 31 Jul 2018
Natera Appoints Roy Baynes to Board of Directors, Adding Deep Oncology Experience
Diagnostics Oncology Personnel
 HSMN NewsFeed - 20 Jul 2018
FDA Grants Approval of TIBSOVO(R), the First Oral, Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH1 Mutation
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 9 Jul 2018
Results of Phase III (PIX306) Trial Evaluating Progression-Free Survival of PIXUVRI(R) (pixantrone) Combined with Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 May 2018
FDA expedites review of Novartis drug Promacta(R) for first-line severe aplastic anemia (SAA)
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 May 2018
TapImmune Creates Scientific Advisory Board to Support Clinical Development of Multi-Antigen Cell Therapy Platform
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 8 May 2018
Daiichi Sankyo Announces Single Agent Quizartinib Significantly Prolongs Overall Survival Compared with Chemotherapy in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations (QuANTUM-R Study)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Feb 2018
Amgen Receives Positive CHMP Opinion For Delivery System Of Neulasta(R) (pegfilgrastim)
Biopharmaceuticals Drug Delivery Regulatory
 HSMN NewsFeed - 22 Jan 2018
Astellas and Vical Announce Top-Line Results for Phase 3 Trial of Cytomegalovirus Vaccine ASP0113 in Hematopoietic Stem Cell Transplant Recipients
Biopharmaceuticals
 HSMN NewsFeed - 17 Jan 2018
Novartis granted US FDA Priority Review for Kymriah(TM) (tisagenlecleucel), formerly CTL019, for adults with r/r DLBCL
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 Dec 2017
DARZALEX(R) (daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Nov 2017
Artemis Therapeutics Receives Orphan Drug Designation From U.S. Food And Drug Administration For Artemisone For The Treatment Of Malaria
Biopharmaceuticals FDA
 HSMN NewsFeed - 9 Aug 2017
Ocugen Receives FDA Orphan Drug Designation for OCU300 (brimonidine tartrate) for the Treatment of Ocular Graft Versus Host Disease
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 30 May 2017
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Mar 2017
Dinutuximab beta receives positive recommendation for the treatment of high-risk neuroblastoma in Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 24 Mar 2017
FDA Grants Approval for BAVENCIO(R) (avelumab), the First Immunotherapy Approved for Metastatic Merkel Cell Carcinoma
Biopharmaceuticals Oncology FDA Product Launch
 HSMN NewsFeed - 15 Mar 2017
FDA Approves Merck’s KEYTRUDA(R) (pembrolizumab) for Adult and Pediatric Patients with Classical Hodgkin Lymphoma (cHL) Refractory to Treatment, or Who Have Relapsed After Three or More Prior Lines of Therapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Mar 2017
Lycera Announces the Appointment of Pablo J. Cagnoni, M.D., to the Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Mar 2017
BLINCYTO(R) (blinatumomab) Significantly Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Compared To Chemotherapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Feb 2017
Actinium Pharmaceuticals Announces Hiring of Steven Price to Position of Vice President, Clinical and Commercial Strategy
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 Jan 2017
Bellicum Announces Appointment of Rick Fair as Chief Executive Officer in Preparation for Commercialization of BPX-501 and Next Phase of Growth
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Jan 2017
Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 Jan 2017
ViraCyte Granted U.S. FDA Fast Track Designation for Viralym-C
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Nov 2016
Conditional Approval from the European Commission to Treat Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 11 Nov 2016
Bristol-Myers Squibb’s Opdivo(R) (nivolumab) is the First Immuno-Oncology Treatment to Receive FDA Approval Based on Overall Survival in Head and Neck Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 26 Oct 2016
Actinium Pharmaceuticals Announces New Hires As Supply Chain Organization Expands To Accommodate Growth
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 14 Oct 2016
Bristol-Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) for the Treatment of Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant and Treatment With Brentuximab Vedotin
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 8 Aug 2016
Takeda Receives Marketing Authorization in Canada for NINLARO(TM) (ixazomib) in Relapsed/Refractory Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 20 Jun 2016
Sangamo BioSciences Announces FDA Clearance of Investigational New Drug Application for ZFN-Mediated Genome Editing Treatment of MPS II
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Jun 2016
Celator Pharmaceuticals(R) Presented Phase 3 Trial Results in Patients with High-Risk Acute Myeloid Leukemia Demonstrating VYXEOS(TM) (CPX-351) Significantly Improved Overall Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 May 2016
Roche announces the first FDA-approved CMV test for use in hematopoietic stem cell transplant recipients
Diagnostics FDA
 HSMN NewsFeed - 14 Mar 2016
ProNAi Therapeutics Granted Orphan Drug Designation for PNT2258 for the Treatment of Diffuse Large B-Cell Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Feb 2016
Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For ZFN-Mediated Genome Editing Treatment Of MPS I
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Jan 2016
Counsyl Appoints Ted Snelgrove as Chief Business Officer
Diagnostics Personnel
 HSMN NewsFeed - 28 Dec 2015
Chimerix Announces Top-Line Results From Phase 3 SUPPRESS Trial of Brincidofovir
Biopharmaceuticals
 HSMN NewsFeed - 21 Dec 2015
Oral REVLIMID(R) Plus Dexamethasone Granted Approval for Treatment of Patients with Newly Diagnosed Multiple Myeloma in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 24 Nov 2015
European Commission Approves Amgen's BLINCYTO(R) (blinatumomab) for the Treatment of Adults with Philadelphia Chromosome-Negative Relapsed or Refractory B-precursor Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 2 Nov 2015
New CyberKnife(R) and TomoTherapy(R) System Data Presented at Leading Scientific Industry Meeting
Devices Oncology
 HSMN NewsFeed - 30 Oct 2015
Celgene’s VIDAZA(R) (Azacitidine for Injection) Approved by the European Commission as New Treatment for Elderly Patients with Acute Myeloid Leukaemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 29 Oct 2015
Bellicum Appoints Alan K. Smith as Senior Vice President of Manufacturing
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 25 Sep 2015
Celgene’s VIDAZA(R) (Azacitidine for Injection) Receives Positive CHMP Opinion as New Treatment for Elderly Patients with Acute Myeloid Leukaemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 17 Aug 2015
European Commission Grants Marketing Authorisation for Unituxin(TM) (dinutuximab) for the Treatment of Paediatric High-Risk Neuroblastoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 15 Jul 2015
Fate Therapeutics Appoints Dr. Stewart Abbot as Vice President, Translational Research
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 May 2015
Jeng-Dar Yang Ph.D. Joins Actinium Pharmaceuticals as Vice President of Pharmaceutical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Apr 2015
ArmaGen Announces FDA Acceptance of IND Application for AGT-181 for the Treatment of Hurler Syndrome
Biopharmaceuticals Neurology
 HSMN NewsFeed - 3 Apr 2015
MD Anderson, Astellas Pharma Sign Option Agreement for Monoclonal Antibody Drug Targeting Acute Myeloid Leukemia
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 20 Feb 2015
REVLIMID(R) (Lenalidomide) Approved by the European Commission for the Treatment of Adult Patients with Previously Untreated Multiple Myeloma who are Not Eligible for Transplant
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 5 Dec 2014
Bellicum Announces New Director, Executive Management Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Sep 2014
CTI BioPharma And Servier Announce Exclusive License And Collaboration Agreement To Develop And Commercialize PIXUVRI(R)
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 27 Aug 2014
Ligand Partner GlaxoSmithKline Receives U.S. FDA Approval for Promacta(R)/Revolade(TM) For Use in Patients with Severe Aplastic Anemia
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Aug 2014
Bellicum Pharmaceuticals Secures $55 Million in Oversubscribed Series C Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 28 Apr 2014
Actinium Announces Key Additions to Senior Management Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 23 Apr 2014
Spectrum Pharmaceuticals’ Pivotal Trial of Captisol-Enabled(TM) (Propylene Glycol-Free) Melphalan Meets Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Feb 2014
Spectrum Pharmaceuticals Announces FDA’s Acceptance of NDA Filing for Beleodaq(TM) (belinostat) for Injection, a novel pan-HDAC inhibitor
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 7 Jan 2014
Bellicum Pharmaceuticals Raises $34.4 Million in a Series B Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 6 Jan 2014
Tekmira Announces Strategic Reorganization to Strengthen Leadership Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Jan 2014
PIXUVRI(R) (pixantrone) Receives Positive Final Appraisal Determination from NICE
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 18 Dec 2013
America Stem Cell, Inc. Changes Its Name to Targazyme, Inc.
Biopharmaceuticals Regenerative Medicine Oncology
 HSMN NewsFeed - 4 Dec 2013
Cell Therapeutics and GKV-SV Reach Agreement on Pricing of PIXUVRI(R) (pixantrone) in Germany
Biopharmaceuticals Oncology Reimbursement
 HSMN NewsFeed - 18 Nov 2013
Merck’s New Drug Application for an Investigational Intravenous (IV) Formulation of NOXAFIL(R) (posaconazole) Receives FDA Priority Review
Biopharmaceuticals FDA Regulatory
 HSMN NewsFeed - 18 Nov 2013
Actinium Pharmaceuticals Announces Plans For Iomab(TM)-B Phase 3 Pivotal Trial Following Meeting With FDA
Biopharmaceuticals
 HSMN NewsFeed - 18 Nov 2013
Kiadis Pharma Provides Positive Update on its Phase II Clinical Program with Blood Cancer Treatment ATIR(TM)
Biopharmaceuticals
 HSMN NewsFeed - 14 Nov 2013
Defibrotide Granted Orphan Drug Status in Australia
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 29 Oct 2013
Pharmalink Receives US Orphan Drug Designation for Busulipo(TM), its Novel Oncology Product for Bone Marrow Transplantation
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Oct 2013
Amgen Acquires Filgrastim Franchise Rights From Roche In 100 Markets
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 22 Oct 2013
Gentium Receives Marketing Authorization From the European Commission for Defitelio(R) (Defibrotide)
Biopharmaceuticals Regulatory Product Launch
 HSMN NewsFeed - 15 Oct 2013
Second Draft NICE Guidance for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI(R) (pixantrone)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 11 Oct 2013
Syndax Names Steven M. Fruchtman, M.D., Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 19 Aug 2013
Market Access Granted in France for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI(R) (pixantrone)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 8 Aug 2013
European Commission Approves VELCADE(R) as a Frontline Induction Therapy before Stem Cell Transplantation
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 26 Jul 2013
Gentium Receives Positive Opinion From EMA's CHMP for Defitelio
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 18 Jul 2013
Celgene Will Discontinue Phase III ORIGIN(R) Trial in Previously Untreated Elderly Patients with B-Cell Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Jul 2013
Market Access Granted in Italy for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI(R) (pixantrone)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 8 Jul 2013
Cell Therapeutics Provides Reimbursement Update for the UK for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI(R) (pixantrone)
Biopharmaceuticals Oncology Reimbursement
 HSMN NewsFeed - 15 Apr 2013
Ambit Biosciences Appoints David Parkinson, M.D., to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Mar 2013
Chimerix Appoints Michael D. Rogers, Ph.D., as Chief Development Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Mar 2013
Spectrum Pharmaceuticals Gains Rights to Pivotal-Stage Captisol-Enabled(R) Melphalan
Biopharmaceuticals Licensing
 HSMN NewsFeed - 21 Feb 2013
Gentium Provides Update on the Review of Defibrotide Marketing Authorization
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 20 Feb 2013
Ernest Mario, Ph.D., Named Chairman of Chimerix, Inc.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Feb 2013
Onyx Pharmaceuticals Appoints Dr. Pablo Cagnoni as Executive Vice President, Global Research & Development and Technical Operations
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 14 Jan 2013
Neuralstem Receives FDA Approval To Commence Spinal Cord Injury Trial
Biopharmaceuticals Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 31 Oct 2012
Takeda and Millennium Announce European Conditional Marketing Authorization for ADCETRIS(R) (Brentuximab Vedotin)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 16 Oct 2012
Clinical Study Validates Sequenta’s LymphoSIGHT(TM) Platform as More Sensitive Alternative to Flow Cytometry for Cancer Detection
Diagnostics Oncology
 HSMN NewsFeed - 15 Oct 2012
Fate Therapeutics Appoints Christian Weyer As President And Chief Executive Officer
Regenerative Medicine Personnel
 HSMN NewsFeed - 11 Sep 2012
Cell Therapeutics Announces European Launch Of Pixuvri(R) For Treatment Of Adult Patients With Multiply Relapsed Or Refractory Aggressive Non-Hodgkin B-Cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Sep 2012
Third Critically Ill Patient Successfully Treated With Pluristem's PLX Cells Under Compassionate Use
Regenerative Medicine Oncology
 HSMN NewsFeed - 23 Aug 2012
Actinium Pharmaceuticals Strengthens Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Aug 2012
Life of Cancer Patient Suffering From Bone Marrow Failure Saved Following Treatment With Pluristem's PLX Cells
Regenerative Medicine Oncology
 HSMN NewsFeed - 27 Jun 2012
PRIMA Study Shows Treatment with Privigen(R) Improved Function in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Biopharmaceuticals
 HSMN NewsFeed - 14 Jun 2012
Cell Therapeutics Appoints New Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 31 May 2012
Cell Therapeutics' Pixuvri(R) Phase 3 Clinical Trial Results Published in The Lancet Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 May 2012
Gentium Appoints PharmaSwiss, S.A. as Exclusive Distributor of Defibrotide in Central and Eastern European Countries
Biopharmaceuticals Distribution
 HSMN NewsFeed - 19 Mar 2012
Genmab Provides Update on Ofatumumab Phase III Head to Head Study in DLBCL
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Mar 2012
Bellicum Closes $20 Million Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 27 Feb 2012
The Lancet Publishes Results from Gentium's Phase III Defibrotide Trial for the Prevention of VOD in Paediatric Patients
Biopharmaceuticals
 HSMN NewsFeed - 9 Jan 2012
Gentium Appoints Swedish Orphan Biovitrum AB as Exclusive Distributor of Defibrotide in Nordic and Baltic Territories
Biopharmaceuticals Distribution
 HSMN NewsFeed - 29 Dec 2011
Gentium Provides Update on MAA Process for Defibrotide in Europe
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 16 Nov 2011
Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Nov 2011
FDA Approves Addition of Sustained Overall Survival Advantage (5-year follow-up) to Label for VELCADE(R) in Patients with Previously Untreated Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 31 Aug 2011
NexBio's DAS181 (Fludase(R)*) Improves Symptoms in Four Severely Immunocompromised Patients With Life-Threatening Parainfluenza Pneumonitis
Biopharmaceuticals
 HSMN NewsFeed - 26 Aug 2011
Medistem Submits Response to FDA Clinical Hold
Regenerative Medicine FDA
 HSMN NewsFeed - 8 Aug 2011
Researchers Find RapidArc(R) Radiotherapy from Varian Medical Systems Can Quickly and Accurately Deliver Total Marrow Irradiation (TMI) Treatments for Patients with Blood Cancers
Devices Oncology
 HSMN NewsFeed - 13 Jun 2011
Spectrum Pharmaceuticals Announces Promotions of Steven M. Fruchtman, MD, to Chief Medical Officer, Head of Medical & Regulatory Affairs, and Nozar Azarnia, PhD, to Head of Biostatistics and Data Management
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Mar 2011
Incyte’s Ruxolitinib (INCB18424) Meets Primary Endpoint in Second Phase III Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Feb 2011
Spectrum Pharmaceuticals Appoints Steven M. Fruchtman, MD, an Industry Veteran, as Vice President of Clinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Sep 2010
Athersys Receives Orphan Drug Designation for MultiStem in Graft vs. Host Disease
Regenerative Medicine FDA
 HSMN NewsFeed - 25 Aug 2010
Neuralstem Files FDA Application for First Chronic Spinal Cord Injury Stem Cell Trial
Regenerative Medicine
 HSMN NewsFeed - 7 Jun 2010
Cytheris Closes 12 Million ($15 Million) Series D Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 1 Mar 2010
Gentium Announces Management Changes and Corporate Restructuring
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Feb 2010
Elbit Imaging Announces Data Monitoring Committee Recommends Continuation of Phase III Study of StemEx(R), a Cord Blood Stem Cell Product, for Leukemia and Lymphoma
Regenerative Medicine Oncology
 HSMN NewsFeed - 19 Jan 2010
QuantRx CEO Provides Update on Genetics-based Personalized Medicine and Disease Prevention Platform Technology
Diagnostics Personalized Medicine
 HSMN NewsFeed - 4 Jan 2010
FDA Approves Addition of Sustained Overall Survival Benefit to Label for VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 15 Dec 2009
Access Pharmaceuticals Appoints Sales and Marketing Executive
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 7 Dec 2009
r4 Vascular Receives FDA 510(k) Clearance to Market the First Power-Injectable Apheresis Catheter
Devices FDA
 HSMN NewsFeed - 7 Dec 2009
Hana Biosciences Announces Positive Data From Pivotal rALLy Clinical Trial of Marqibo(R) in Acute Lymphoblastic Leukemia at 51st American Society of Hematology Annual Meeting
Biopharmaceuticals Drug Delivery Oncology
 HSMN NewsFeed - 23 Nov 2009
Inimex Announces Appointment of New CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Oct 2009
Institute Curie Hospital Purchases Second TomoTherapy(R) Radiation Therapy System
Devices Oncology
 HSMN NewsFeed - 18 Sep 2009
FDA Grants Priority Review Status to Supplement Containing Long-Term Survival Data for VELCADE(R) (bortezomib) for Injection
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 Sep 2009
Stem Cell Therapy International Inc. Announces Histostem Litigation Settlement
Regenerative Medicine Litigation Mergers & Acquisitions
 HSMN NewsFeed - 8 Sep 2009
Osiris Therapeutics Announces Preliminary Results for Prochymal Phase III GvHD Trials
Biopharmaceuticals
 HSMN NewsFeed - 2 Sep 2009
FDA to Review Supplement Containing Long-Term Survival Data For VELCADE(R) (bortezomib) For Injection
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 19 Aug 2009
Gentium Reports Top Line Results from the Phase III Treatment Trial of Defibrotide for Severe Veno-Occlusive Disease
Biopharmaceuticals
 HSMN NewsFeed - 4 Aug 2009
DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Jul 2009
Access Pharmaceuticals Announces New MuGard Commercial Strategy in North America
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Jul 2009
Access Pharmaceuticals Announces Commercial Launch of MuGard(TM) in Norway by SpePharm
Biopharmaceuticals
 HSMN NewsFeed - 23 Jul 2009
MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 Mar 2009
EUSA Pharma Completes the European Launch of CAPHOSOL(R) for Prevention and Treatment of Oral Mucositis Caused by Cancer Therapy
Biopharmaceuticals
 HSMN NewsFeed - 19 Feb 2009
Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
Biopharmaceuticals Licensing
 HSMN NewsFeed - 13 Feb 2009
ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
Biopharmaceuticals
 HSMN NewsFeed - 9 Feb 2009
ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
Biopharmaceuticals
 HSMN NewsFeed - 15 Jan 2009
Osiris Receives FDA Clearance to Broaden Prochymal Expanded Access Program
Regenerative Medicine FDA
 HSMN NewsFeed - 15 Dec 2008
FDA Approves Genzyme's Mozobil
Biopharmaceuticals FDA
 HSMN NewsFeed - 9 Dec 2008
Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Dec 2008
Vion Pharmaceuticals Adds Tanya Lewis to Senior Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Oct 2008
Cancer Drug Vidaza(R) Receives Positive Opinion from European Regulatory Authority for Treatment of MDS and AML
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 17 Sep 2008
DOR BioPharma Forms orBec(R) European Medical Advisory Board
Biopharmaceuticals
 HSMN NewsFeed - 9 Jun 2008
Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2008
Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2008
MethylGene Reports Clinical Data for MGCD0103 at the 44th American Society of Clinical Oncology (ASCO) Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Jun 2008
Updated REVLIMID(R) Data Presented in Newly Diagnosed Multiple Myeloma Presented at the 2008 American Society of Clinical Oncology (ASCO) Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2008
New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 May 2008
StemCells Confirms Previously Reported Batten Trial Death Was Due to Natural Progression of Disease
Regenerative Medicine Nurology
 HSMN NewsFeed - 7 May 2008
Astellas' Mycamine(R) (micafungin) Licensed for Use in Europe to Treat Serious Fungal Infections
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 6 May 2008
REGiMMUNE Raises $8,000,000 in Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 23 Apr 2008
Stem Cell Therapy International Amends Merger With Histostem
Regenerative Medicine Mergers & Acquisitions
 HSMN NewsFeed - 18 Mar 2008
Immunomedics' Milatuzumab Receives FDA Orphan Drug Designation for Therapy of Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Mar 2008
Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Feb 2008
Stem Cell Therapy International Signs Memorandum of Intent to Merge With a Leading Umbilical Cord Stem Cell Company Histostem, Co., Ltd. of Korea
Regenerative Medicine Mergers & Acquisitions
 HSMN NewsFeed - 14 Feb 2008
MethylGene and Pharmion Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Feb 2008
Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Feb 2008
Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 11 Feb 2008
MethylGene and Pharmion Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 4 Feb 2008
Vion Pharmaceuticals Adds William Hahne, M.D. to Senior Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Jan 2008
FDA Grants Priority Review For Velcade(R) (bortezomib) for Injection In Patients with Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Jan 2008
Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 23 Jan 2008
FDA Approves Additional Indication for Astellas' MYCAMINE(R)
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Jan 2008
Vion Pharmaceuticals Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed AML
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jan 2008
DOR BioPharma Receives Orphan Drug Designation for Oral BDP for the Treatment of Pediatric Crohn's Disease
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 17 Dec 2007
Otsuka Pharmaceutical Acquires Rights to IV Busulfex From PDL BioPharma
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 10 Dec 2007
VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Dec 2007
Osiris Therapeutics Reports Positive Results for Prochymal(TM) as a Rescue Agent in Pediatric Patients with End-Stage Graft vs. Host Disease
Regenerative Medicine
 HSMN NewsFeed - 9 Dec 2007
Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Dec 2007
Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Dec 2007
DOR BioPharma Announces Results of orBec(R) End of Review Conference With the FDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Nov 2007
New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Nov 2007
ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 29 Oct 2007
St. Joseph Hospital Selects IntraOp Medical's Mobetron to Deliver Advanced Cancer Treatment
Devices Oncology
 HSMN NewsFeed - 23 Oct 2007
NCCN Updates Multiple Myeloma Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Oct 2007
Linkage Biosciences Completes Seed Financing
Diagnostics Venture Capital
 HSMN NewsFeed - 9 Oct 2007
orBec(R) Clinical Summary Published in "Expert Opinion on Investigational Drugs"
Biopharmaceuticals
 HSMN NewsFeed - 1 Oct 2007
Axcan Licenses Rights to Cx401, an Innovative Biological Product in Development for the Treatment of Perianal Fistulas, a Significant Unmet Medical Need
Biopharmaceuticals Regenerative Medicine
 HSMN NewsFeed - 18 Sep 2007
New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
Biopharmaceuticals
 HSMN NewsFeed - 18 Sep 2007
Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Aug 2007
Hana Biosciences Receives Fast Track Designation for Marqibo for the Treatment of Relapsed Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Aug 2007
Stem Cell Therapy International Acquires Exclusive Worldwide Rights to New, Anti-Rejection Stem Cell Technology
Regenerative Medicine
 HSMN NewsFeed - 19 Jul 2007
Genzyme Announces Phase 3 Trial of Mozobil in non-Hodgkin's Lymphoma Meets Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Jul 2007
Millennium Initiates Phase III Trial to Determine the Optimal VELCADE(R) (Bortezomib) for Injection Based Therapy in Newly Diagnosed Multiple Myeloma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Jul 2007
StemCyte Appoints Robert Dickey IV as Senior Vice President and Chief Financial Officer
Regenerative Medicine Personnel
 HSMN NewsFeed - 5 Jul 2007
ViroPharma Initiates Phase 3 Study of CAMVIA(TM) (maribavir) in Liver Transplant Patients
Biopharmaceuticals
 HSMN NewsFeed - 2 Jul 2007
VELCADE(R) (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Jun 2007
VELCADE(R) (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Jun 2007
VELCADE(R) (Bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Jun 2007
Bio-Matrix Scientific Group, Inc.'s Dr. Geoffrey O'Neill Sees Promise in New Studies for Producing Embryonic-Like Stem Cells from Skin Cells
Regenerative Medicine
 HSMN NewsFeed - 13 Jun 2007
"The Group Room(R)" Cancer Talk Radio Show to Broadcast Follow-up Special to the 12th Congress of the European Hematology Association (EHA)
Oncology
 HSMN NewsFeed - 4 Jun 2007
8-Year Long-Term Data Demonstrate Prolonged Overall Survival and Length of Disease Remission With Bexxar(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Phase 2 Clinical Results of Ganite(R) Plus Standard Therapy in Patients with Relapsed/Refractory Lymphoma Presented at ASCO
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
VELCADE(R) (Bortezomib) for Injection Based Therapy Substantially Improves Event-Free Survival and Complete Response Rate in Newly Diagnosed Multiple Myeloma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 May 2007
Neuralstem's Cells Restore Motor Function in Spinal Ischemia-Paralyzed Rats
Regenerative Medicine
 HSMN NewsFeed - 9 May 2007
FDA Advisory Panel Reviews DOR BioPharma's orBec(R) for Treatment of GI GVHD
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Apr 2007
NCCN Updates Prevention and Treatment of Cancer-Related Infections Guidelines
Oncology
 HSMN NewsFeed - 24 Apr 2007
Axon Labs Names David P. Dickinson as Chief Executive Officer
Devices Personnel
 HSMN NewsFeed - 21 Mar 2007
Bio Stem, Inc. to Obtain One of the Largest Stem Cell Inventories in the World Through Merger
Regenerative Medicine Mergers & Acquisitions
 HSMN NewsFeed - 20 Mar 2007
New Cancer Practice Guidelines Recommend NOXAFIL(R) (Posaconazole) for Antifungal Prophylaxis in Certain High-Risk Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Mar 2007
DOR BioPharma Forms orBec(R) Medical Advisory Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Feb 2007
NCCN Updates Myelodysplastic Syndromes (MDS) Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Feb 2007
Favrille Announces Agreement With Berlex, Inc. Regarding Use of FavId(R) in Combination With Leukine(R) (sargramostim) in B-Cell Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Feb 2007
Favrille Announces Long-Term Follow-Up Data From Phase 2 Clinical Trial of FavId Following Autologous Stem Cell Transplantation for B-Cell Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Feb 2007
ViroPharma Receives Orphan Drug Designation for Maribavir for Cytomegalovirus Viremia and Disease Indication
Biopharmaceuticals FDA
 HSMN NewsFeed - 31 Jan 2007
FDA Advisory Committee to Review DOR BioPharma's orBec(R) for the Treatment of GI GVHD
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Jan 2007
TetraLogic Pharmaceuticals Appoints Dr. Andrew Pecora to Its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Jan 2007
The New England Journal Of Medicine Publishes Two Landmark Studies Of NOXAFIL(R) (Posaconazole) in the Prevention of Invasive Fungal Infections
Biopharmaceuticals
 HSMN NewsFeed - 22 Jan 2007
ViaCell Appoints Kirk Williamson as Vice President of Marketing
Regenerative Medicine Personnel
 HSMN NewsFeed - 12 Jan 2007
Astellas Pharma US, Inc. Announces Availability of MYCAMINE(R) 100mg Vial
Biopharmaceuticals
 HSMN NewsFeed - 10 Jan 2007
GenesisBPS Announces the North American Distribution and FDA 510K Clearance of the SEPAX Cell Separation System for Cord Blood Processing
Devices FDA
 HSMN NewsFeed - 3 Jan 2007
Gentium Acquires Italian Defibrotide Marketing Rights from Crinos
Biopharmaceuticals
 HSMN NewsFeed - 26 Dec 2006
Astellas Pharma US, Inc. Submits Supplemental New Drug Application For Antifungal Product MYCAMINE(R)
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Dec 2006
Positive Results from Combination Trials Build on VELCADE(R) (Bortezomib) for Injection Proven Single-Agent Strength in Relapsed Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Dec 2006
VELCADE(R) (Bortezomib) for Injection Combination Shows High Complete and Near Complete Response Rate in Preliminary Data From Phase III Front-Line Multiple Myeloma Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Dec 2006
49 Abstracts Evaluating Revlimid(R) To Be Presented at The 48th American Society of Hematology Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Dec 2006
Publications Feature VELCADE(R) (Bortezomib) for Injection Strength In Hematological Cancers
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Nov 2006
Stem Cell Therapy International Reports the Successful Treatment of a Stroke Patient With Their Proprietary Stem Cell Transplantation Therapy
Regenerative Medicine Neurology
 HSMN NewsFeed - 28 Nov 2006
European Medicines Agency Accepts DOR BioPharma's MAA Filing for orBec(R)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 21 Nov 2006
FDA Accepts DOR BioPharma's NDA Filing for orBec(R)
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 16 Nov 2006
Bioheart, Inc. Expands Clinical Trials of Adult Myogenic Stem Cell Treatment for Heart Attack and Advanced Heart Failure Patients
Regenerative Medicine Cardiology
 HSMN NewsFeed - 16 Nov 2006
CuraGen and TopoTarget Announce Initiation of NCI-sponsored Phase II Clinical Trial of PXD101 for Myelodysplastic Syndrome
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Nov 2006
StemCells, Inc. Announces First Human Neural Stem Cell Transplant
Regenerative Medicine Neurology
 HSMN NewsFeed - 9 Nov 2006
Osiris Therapeutics Reports Positive Phase II Results Using PROCHYMAL(TM) for the Treatment of Acute Graft vs. Host Disease
Biopharmaceuticals Regenerative Medicine
 HSMN NewsFeed - 9 Nov 2006
Noxafil(R) (Posaconazole) Oral Suspension Approved in European Union for Prevention of Invasive Fungal Infections
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 7 Nov 2006
Genzyme Completes Tender Offer for Outstanding Shares of AnorMED
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 7 Nov 2006
DOR BioPharma Submits European Marketing Application for orBec(R) to Treat GI Graft-Versus-Host Disease
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 6 Nov 2006
Elbit Medical Group Announces Receipt of a Special Protocol Assessment From the FDA to Gamida Cell's Stemex(R) Registration Study
Regenerative Medicine FDA
 HSMN NewsFeed - 2 Nov 2006
Gamida Cell's StemEx(R) Registration Study Receives Special Protocol Assessment from the FDA
Regenerative Medicine FDA
 HSMN NewsFeed - 2 Nov 2006
Enzon Pharmaceuticals Announces Second Investigational New Drug Application Approved for Novel rhMBL
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Oct 2006
Schering-Plough Announces FDA Approval of NOXAFIL(R) (Posaconazole) for Treatment of Oropharyngeal Candidiasis (OPC)
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 Oct 2006
Gleevec(R) Approved in the US for Five Rare Life-Threatening Disorders With Limited Treatment Options
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 19 Oct 2006
New Landmark Study Shows the Use of a BiovaxID Formulation Improves Disease Free survival in 80% of Patients Whose Cancer has Relapsed after Chemotherapy Administered With or Without Rituxan
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Oct 2006
Genzyme and AnorMED Reach Agreement on Acquisition
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 12 Oct 2006
EKR Therapeutics Acquires Exclusive License for Gelclair(R) from Helsinn Healthcare SA
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 11 Oct 2006
AnorMED has determined Genzyme's offer is a 'superior proposal'
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 11 Oct 2006
Cytogen Acquires North American Marketing Rights to CAPHOSOL(R) for Treatment of Both Oral Mucositis and Dry Mouth
Biopharmaceuticals Licensing
 HSMN NewsFeed - 10 Oct 2006
Genzyme Announces Proposal to Increase Its Offer to Acquire AnorMED to $13.50 Per Share in Cash
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 4 Oct 2006
Schering AG and Biogen Idec Announce Start of the ZEAL Phase III Clinical Trial With Anti-Cancer Drug Zevalin(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Oct 2006
Updated REVLIMID(R) (lenalidomide) Clinical Results Presented at the 3rd International Conference on Innovative Therapies for Lymphoid Malignancies
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Sep 2006
Xenomics Announces Development of Test for the Genetic Marker for Acute Myeloid Leukemia (AML)
Diagnostics Oncology
 HSMN NewsFeed - 28 Sep 2006
ViroPharma Initiates First of Two Phase 3 Studies of Maribavir in Transplant Patients
Biopharmaceuticals
 HSMN NewsFeed - 26 Sep 2006
Millennium Agrees to Acquire AnorMED, Adding Phase III Oncology Product with Planned Near Term Launch Date
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 25 Sep 2006
Approval of FOSRENOL in the United Kingdom triggers U.S.$3 million payment to AnorMED
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 22 Sep 2006
DOR BioPharma Files New Drug Application with FDA to Market orBec for GI GVHD
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Sep 2006
European Union's CHMP Adopts Positive Opinion for NOXAFIL(R) (posaconazole) Oral Suspension for Prevention of Invasive Fungal Infections
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 21 Sep 2006
Latest Data Confirm Benefits of Evoltra(R) in Children with Relapsed/Refractory Acute Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Sep 2006
AnorMED amends license agreement for cancer drug
Biopharmaceuticals Licensing
 HSMN NewsFeed - 18 Sep 2006
European Commission Grants Orphan Medicinal Product Designation to Nektar's Amphotericin B Inhalation Powder (ABIP) for the Prevention of Pulmonary Fungal Infections in Patients Deemed At Risk
Biopharmaceuticals Drug Delivery Regulatory
 HSMN NewsFeed - 18 Sep 2006
Schering-Plough Announces FDA Approval of NOXAFIL(R) (Posaconazole) for Prevention of Invasive Fungal Infections
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 Sep 2006
Combination of High Dose QUADRAMET(R) and Chemotherapy Shows Promise for Treatment of High-Risk Acute Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Jul 2006
Stem Cell Authority Ltd.(TM) Offers Ethical Alternative to Alleviate Political Stem Cell Deadlock Between U.S. Congress and President
Regenerative Medicine
 HSMN NewsFeed - 20 Jul 2006
Stem Cell Therapy International Names Lixian (John) Jiang, Chief Operating Officer, China Division
Regenerative Medicine Personnel
 HSMN NewsFeed - 11 Jul 2006
Gentium Announces Publication of Two Independent Pediatric Studies of Defibrotide
Biopharmaceuticals
 HSMN NewsFeed - 10 Jul 2006
AnorMED completes enrollment in Phase III trial for MOZOBIL in stem cell transplant in multiple myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2006
ThermoGenesis & NETCORD Note U.S. Patent Office's Rejection of PharmaStem Cord Blood Stem Cell Patent Claims
Devices Regenerative Medicine Litigation
 HSMN NewsFeed - 30 May 2006
ViaCell Announces New Office Actions Rejecting PharmaStem Patent Claims
Regenerative Medicine Litigation
 HSMN NewsFeed - 25 May 2006
Gentium Strengthens U.S. Presence and Adds Personnel
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 May 2006
AnorMED President and CEO Michael Abrams steps down
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 May 2006
FDA Grants Fast Track Designation to Nektar's Amphotericin B Inhalation Powder (ABIP) for Prevention of Pulmonary Fungal Infections in At-Risk Patients
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 May 2006
Five years after approval, Gleevec underscores the promise of targeted therapy to provide sustained disease control
Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 124

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 124 additional stories matching:
stem cell transplant
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.